๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Results of total body irradiation in the treatment of advanced non-Hodgkin's lymphomas

โœ Scribed by Steven C. Carabell; John T. Chaffey; David S. Rosenthal; William C. Moloney; Samuel Hellman


Publisher
John Wiley and Sons
Year
1979
Tongue
English
Weight
493 KB
Volume
43
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis


Total body irradiation (TBI) was used as primary therapy for 58 previously untreated patients with Stage III or IV non-Hodgkin's lymphoma (NHL). 150 rad was administered, with 15 rad fractions twice a week, with careful monitoring of hematologic status. Thrombocytopenia was the most frequent complication, which resolved in all except 4 patients. Survival at 8 years was 52%, with 14% relapse-free survival. Patients with nodular histology had a more favorable prognosis than those with diffuse histology (median relapse-free survival of 24 vs. 12 months). There were 2 cases of erythroleukemia, which occurred after combination chemotherapy was given for relapse. Though TBI can offer complete remission and extended survival in advanced NHL, most patients eventually relapse and it should not be considered as a curative mode of therapy.


๐Ÿ“œ SIMILAR VOLUMES


The treatment of non-Hodgkin's lymphoma
โœ Samuel Hellman; David S. Rosenthal; William C. Moloney; John T. Chaffey ๐Ÿ“‚ Article ๐Ÿ“… 1975 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 432 KB ๐Ÿ‘ 2 views

Much of the approach to evaluation and management of the non-Hodgkin's lymphomas has been modeled after Hodgkin's disease. However, as the name implies, they are quite different. The non-Hodgkin's lymphomas are a group of diseases and syndromes. These many different presentations, syndromes, and pos

Treatment of non-Hodgkin's lymphoma in t
โœ Umberto Tirelli; Vittorina Zagonel; Domenico Errante; Lucia Fratino; Silvio Monf ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 166 KB ๐Ÿ‘ 2 views

Recent studies specifically directed toward assessing the outcome of older patients with non-Hodgkin's lymphoma (NHL) indicate that age per se is an important and independent prognostic factor for response and survival. We report a review of the clinical trials of the literature and the Aviano Group